T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Lamb Weston
LW
$7.33B
| $13.7M | ﹤0.01% |
215,585
-21,311
| -9% | -$1.23M |
|
|
GTM
1352
ZoomInfo Technologies
GTM
$1.2B
| $13.7M | ﹤0.01% |
212,700
+27,444
| +15% | +$1.84M |
|
1353
ePlus
PLUS
$2.31B
| $13.6M | ﹤0.01% |
251,928
-60
| -0% | -$3.31K |
|
|
LIAN
1354
DELISTED
LianBio American Depositary Shares
LIAN
| $13.4M | ﹤0.01% |
+2,242,389
| New | +$25.6M |
|
1355
Ambev
ABEV
$43B
| $13.4M | ﹤0.01% |
4,786,300
+75,700
| +2% | +$217K |
|
|
CCXI
1356
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.4M | ﹤0.01% |
367,423
-9,199
| -2% | -$323K |
|
1357
Natera
NTRA
$44.7B
| $13.4M | ﹤0.01% |
143,021
-3,842
| -3% | -$399K |
|
1358
WEX
WEX
$6.57B
| $13.3M | ﹤0.01% |
94,992
+2,055
| +2% | +$314K |
|
1359
PENN Entertainment
PENN
$2.52B
| $13.3M | ﹤0.01% |
256,126
-188,818
| -42% | -$11.4M |
|
1360
Pinnacle West Capital
PNW
$12.3B
| $13.3M | ﹤0.01% |
187,834
-7,171
| -4% | -$482K |
|
1361
JD.com
JD
$39.2B
| $13.2M | ﹤0.01% |
188,402
-21,733
| -10% | -$1.72M |
|
1362
GeneDx Holdings
WGS
$2.33B
| $13.1M | ﹤0.01% |
88,865
+2,428
| +3% | +$542K |
|
1363
Invitation Homes
INVH
$18B
| $13M | ﹤0.01% |
287,807
+1,153
| +0.4% | +$47.6K |
|
1364
Immunocore
IMCR
$1.73B
| $13M | ﹤0.01% |
379,891
+17,865
| +5% | +$647K |
|
1365
Protagonist Therapeutics
PTGX
$9.99B
| $12.9M | ﹤0.01% |
377,132
-114,509
| -23% | -$3.62M |
|
1366
PVH
PVH
$3.79B
| $12.8M | ﹤0.01% |
120,222
-3,671
| -3% | -$401K |
|
1367
Molson Coors Class B
TAP
$7.97B
| $12.8M | ﹤0.01% |
275,265
-13,032
| -5% | -$598K |
|
1368
Sprott Physical Gold and Silver Trust
CEF
$8.22B
| $12.7M | ﹤0.01% |
715,877
-342,485
| -32% | -$6.08M |
|
1369
United Therapeutics
UTHR
$21.4B
| $12.7M | ﹤0.01% |
58,718
-1,516
| -3% | -$298K |
|
1370
Newell Brands
NWL
$2.62B
| $12.7M | ﹤0.01% |
580,288
-34,367
| -6% | -$776K |
|
1371
Genpact
G
$5.71B
| $12.6M | ﹤0.01% |
237,607
-5,925
| -2% | -$298K |
|
|
INFA
1372
DELISTED
Informatica
INFA
| $12.5M | ﹤0.01% |
+339,066
| New | +$11.5M |
|
1373
Canadian National Railway
CNI
$76.8B
| $12.3M | ﹤0.01% |
100,373
+39,390
| +65% | +$4.99M |
|
|
WHWK
1374
Whitehawk Therapeutics
WHWK
$251M
| $12.3M | ﹤0.01% |
508,892
+43,293
| +9% | +$1.09M |
|
1375
Credicorp
BAP
$30.8B
| $12.2M | ﹤0.01% |
99,597
-1,574,605
| -94% | -$193M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.